Induction of cytotoxic T lymphocyte responses by cholera toxin-treated bone marrow-derived dendritic cells

Vaccine

Volumn 21, Issue 15, 2003, Pages 1613-1619

  Jang, Myoung Ho ^a   Kweon, Mi Na ^a   Hiroi, Takachika ^a   Yamamoto, Masafumi ^a,b   Takahashi, Ichiro ^a,c   Kiyono, Hiroshi ^a,d  

^a OSAKA UNIVERSITY   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

B7 1; Cholera toxin; CTL; Dendritic cells

Indexed keywords

CD40 ANTIGEN; CD8 ANTIGEN; CHOLERA TOXIN; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY;

ANIMAL CELL; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CELL CULTURE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BONE MARROW CELLS; CELLS, CULTURED; CHOLERA TOXIN; DENDRITIC CELLS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0037413962     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00734-X     Document Type: Article

References (47)

1. Gallucci S., Matzinger P. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13(1):2001;114-119.
2. Banchereau J., Steinman R. Dendritic cells and the control of immunity. Nature. 392(6673):1998;245-252.
3. Gallucci S., Lolkema M., Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5(11):1999;1249-1255.
4. Reis e Sousa C., Sher A., Kaye P. The role of dendritic cells in the induction and regulation of immunity to microbial infection. Curr. Opin. Immunol. 11(4):1999;392-399.
5. Jackson R.J., Fujihashi K., Xu-Amano J., Kiyono H., McGhee J.R. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect. Immun. 61:1993;4272-4279.
6. Lycke N., Holmgren J. Intestinal mucosal memory and presence of memory cells in lamina propria and Peyer's patches in mice two years after oral immunization with cholera toxin. Scand. J. Immunol. 23:1986;611.
7. Lycke N., Tsuji T., Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22:1992;2277-2281.
8. Marinaro M., Staats H.F., Hiroi T.et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155:1995;4621-4629.
9. Braun M.C., He J., Wu C.Y., Kelsall B.L. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor β1 and β2 chain expression. J. Exp. Med. 189(3):1999;541-552.
10. Gagliardi M., Sallusto F., Marinaro M., Langenkamp A., Lanzavecchia A., Magistris M.D. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur. J. Immunol. 30(8):2000;2394-2403.
11. Kuchroo V., Das M., Brown J.et al. B7-1 and B7-2 co-stimulatory molecules activate differentially the Th1/Th2 developmental pathway: application to autoimmune disease therapy. Cell. 80(5):1995;707-718.
12. Freeman G.J., Boussiotis V.A., Anumanthan A.et al. B7-1 and B7-2 do not deliver identical co-stimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity. 2(5):1995;523-532.
13. Yamamoto M., Kiyono H., Yamamoto S.et al. Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant. J. Immunol. 162(12):1999;7015-7021.
14. Cong Y., Weaver C., Elson C. The mucosal adjuvanticity of cholera toxin involves enhancement of co-stimulatory activity by selective up-regulation of B7-2 expression. J. Immunol. 159(11):1997;5301-5308.
15. Yamamoto M., Briles D.E., Yamamoto S., Ohmura M., Kiyono H., McGhee J.R. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J. Immunol. 161(8):1998;4115-4121.
16. Yamamoto S., Kiyono H., Yamamoto M.et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. U.S.A. 94:1997;5267-5272.
17. Yamamoto S., Takeda Y., Yamamoto M.et al. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med. 185:1997;1203-1210.
18. Xu-Amano J., Kiyono H., Jackson R.J.et al. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J. Exp. Med. 178(4):1993;1309-1320.
19. Porgador A., Staats H.F., Itoh Y., Kelsall B.L. Intranasal immunization with cytotoxic T lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue. Infect. Immun. 66(12):1998;5876-5881.
20. Simmons C., Mastroeni P., Fowler R.et al. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J. Immunol. 163(12):1999;6502-6510.
21. + T cell responses. J. Immunol. 166(2):2001;1106-1113.
22. Staats H.F., Bradney C.P., Gwinn W.M.et al. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J. Immunol. 167(9):2001;5386-5394.
23. Belyakov I.M., Derby M.A., Ahlers J.D.et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl. Acad. Sci. U.S.A. 95(4):1998;1709-1714.
24. Chambers C.A., Allison J.P. Co-stimulation in T cell responses. Curr. Opin. Immunol. 9(3):1997;396-404.
25. Lenschow D.J., Walunas T.L., Bluestone J.A. CD28-B7 system of T cell costimulation. Annu. Rev. Immunol. 14:1996;233-258.
26. + murine T cells. I. Development of cytolytic activity. Immunol. Res. 13(4):1994;215-233.
27. + cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. 177(6):1993;1791-1796.
28. Sato M., Iwakabe K., Ohta A.et al. Functional heterogeneity among bone marrow-derived dendritic cells conditioned by T(h)1- and T(h)2-biasing cytokines for the generation of allogeneic cytotoxic T lymphocytes. Int. Immunol. 12(3):2000;335-342.
29. + T cell responses. Nat. Med. 7(2):2001;206-214.
30. Selin L.K., Lin M.Y., Kraemer K.A.et al. Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity. 11(6):1999;733-742.
31. Bennett S., Carbone F., Karamalis F., Flavell R., Miller J., Heath W. Help for cytotoxic-T cell responses is mediated by CD40 signalling. Nature. 393(6684):1998;478-480.
32. Schoenberger S., Toes R., Voort E.v.d., Offringa R., Melief C. T cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 393(6684):1998;480-483.
33. Agren L.C., Ekman L., Lowenadler B., Lycke N.Y. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 158(8):1997;3936-3946.
34. Lassila O., Vainio O., Matzinger P. Can B cells turn on virgin T cells? Nature. 334(6179):1988;253-255.
35. + T lymphocytes in the P815 tumor system in vitro. J. Immunol. 156(2):1996;465-472.
36. Matulonis U., Dosiou C., Freeman G.et al. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 156(3):1996;1126-1131.
37. + TCR-transgenic T cells. J. Immunol. 161(10):1998;5268-5275.
38. Corr M., Tighe H., Lee D.et al. Costimulation provided by DNA immunization enhances antitumor immunity. J. Immunol. 159(10):1997;4999-5004.
39. + help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188(12):1998;2199-2204.
40. + T cell help. J. Exp. Med. 186(1):1997;65-70.
41. Maecker H.T., Umetsu D.T., DeKruyff R.H., Levy S. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC. J. Immunol. 161(12):1998;6532-6536.
42. + T cells. J. Exp. Med. 184(3):1996;863-871.
43. Smith R.E., Donachie A.M., Grdic D., Lycke N., Mowat A.M. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. J. Immunol. 162(9):1999;5536-5546.
44. Ahlers J.D., Dunlop N., Alling D.W., Nara P.L., Berzofsky J.A. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-α synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J. Immunol. 158(8):1997;3947-3958.
45. Iwasaki A., Stiernholm B.J., Chan A.K., Berinstein N.L., Barber B.H. Enhanced CTL responses mediated by plasmid DNA immunogens encoding co-stimulatory molecules and cytokines. J. Immunol. 158(10):1997;4591-4601.
46. Magram J., Connaughton S.E., Warrier R.R.et al. IL-12-deficient mice are defective in IFN-γ production and type 1 cytokine responses. Immunity. 4(5):1996;471-481.
47. Piccotti J.R., Li K., Chan S.Y.et al. Alloantigen-reactive Th1 development in IL-12-deficient mice. J. Immunol. 160(3):1998;1132-1138.